drugset / Trial / NCT03580278
A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this first-in-human study of the formulation ABY-035/AFO2 is to investigate the safety, tolerability and efficacy after multiple doses in sequential escalating dose cohorts in psoriasis subjects.
Timeline
- Start
- 2019-11-13
- Primary completion
- 2020-09-22
- Completion
- 2020-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Izokibep | Protein / enzyme biologic | 75 mg | — |
| Subject | Izokibep | Protein / enzyme biologic | 150 mg | — |